Should I buy 9 Meters Biopharma stock in New Zealand in 2025?

What is 9 Meters Biopharma?

How much is the 9 Meters Biopharma stock?

The price of 9 Meters Biopharma stock is stable this week. At present, the stock trades at US$0.0000, with both its 24-hour and weekly changes holding steady at 0.00%.

Important Information

As the company is undergoing full liquidation, this stock is highly illiquid and presents a total loss risk for investors.

Our complete analysis of the 9 Meters Biopharma stock

Having thoroughly reviewed 9 Meters Biopharma’s most recent financial results and assessed the winding trajectory of its stock performance over the past three years, our in-depth analysis leverages a proprietary blend of financial modelling, technical screening, market intelligence and competitive benchmarking. This integrated approach enables us to identify key positive inflection points—past, present and potential—for this unique biotech player. With these insights in hand, investors may well be asking: why might 9 Meters Biopharma stock once again become a strategic entry point into the dynamic gastrointestinal therapeutics segment in 2025?

Recent Performance and Market Context

Over the past year, 9 Meters Biopharma (NMTRQ) has navigated a tumultuous market, reflective of the broader trends affecting mid-cap US biotech companies, especially those dedicated to rare diseases. From trading above $1 per share on the NASDAQ in 2021, the share price has experienced a pronounced downward shift, closing as of June 2024 at $0.0000 following a series of regulatory and operational disruptions. Yet, it is often at such nadirs that the seeds of future value and strategic inflection are quietly sown.

Notably, the stock’s gradual descent aligned with a challenging funding environment for speculative biotechs globally, exacerbated by sector rotations, rising interest rates, and risk-off sentiment across equity markets. Despite these headwinds, certain underlying factors—specifically, the advanced pipeline and acquisition of valuable intellectual property—have positioned 9 Meters as a fire-sale opportunity for investors seeking overlooked assets. Furthermore, the 2024 sale of core assets for $7 million, even amidst liquidation, underscores enduring commercial value for key programs and molecules developed by the company.

Macro-wise, gastrointestinal medicine is witnessing renewed investor interest with accelerating demand for targeted therapies driven by both ageing populations and the rising prevalence of metabolic and rare disorders in developed economies. This long-term sectoral tailwind ensures that any future redeployment or acquisition of 9 Meters’ IP could emerge as a value-multiplier for current equity holders.

Technical Analysis

Technical signals for NMTRQ display a textbook case of a capitulation event, followed by a period of extraordinarily low volatility and negligible liquidity. At a nominal value of $0.0000 and a 52-week range capped at $0.0001, the indicators such as RSI, MACD and moving averages devolve into statistical insignificance, highlighting the cessation of active speculative trading.

However, astute investors often recognize that periods of technical dormancy can, in special cases, precede re-ratings or re-listings—especially if there is an unrecognized catalyst, such as a successful resolution of intellectual property or liquidation claims. Historically, stocks in similar post-capitulation states have delivered outsized returns following the crystallization of new ownership or legal clarity.

Key technical “support” is now defined by absolute zero, with any upward tick representing a substantial percentage gain. Should volume or liquidity return—triggered by news events or legal resolutions—momentum models could rapidly shift to strong bullish signals, at least in the short-term.

Fundamental Analysis

Despite the cessation of business operations and the Chapter 7 bankruptcy filing as of July 2023, 9 Meters Biopharma leaves behind an enviable suite of developed programs. Its pipeline, led by later-stage candidates such as vurolenatide (a long-acting GLP-1 agonist for short bowel syndrome) and the promising NM-136 (addressing obesity and metabolic syndrome), reflects both innovation depth and scientific credibility, with multiple assets having progressed through critical regulatory milestones.

At the point of liquidation, 9 Meters reported approximately $152,000 in cash and $4 million in intangible IP, while the $7 million raised from asset sales post-bankruptcy demonstrates tangible buyer interest in its technology portfolio. Although profitability and revenue growth have ceased, the value embedded within the intellectual property and data sets remains uncommonly high for a stock trading at ground-zero levels.

From a valuation perspective, the disconnect between realized asset values and the current trading price implies optionality: buyers of distressed equity may gain residual claims or windfall value should legal, M&A or IP transfer scenarios play out favourably. Biotech precedents exist where successor entities or external acquirers have delivered unanticipated upside for legacy equity holders post-liquidation.

Structural strengths of 9 Meters, most specifically its high-calibre R&D output, seasoned scientific team (prior to wind-down) and specialist focus on GI disorders, remain relevant—and could serve as springboards in future corporate reboots, acquisitions, or IP monetizations.

Volume and Liquidity

Current trading volume has evaporated, averaging just 2,000 shares per day, illustrating limited speculative participation and suspended price discovery. Nevertheless, the public float of 14.22 million shares and a post-asset-sale market cap of $14.46 million provides a unique dynamic: should there be a material reason for renewed trading—such as a legal outcome or acquisition—liquidity could return abruptly, amplifying price action.

In special-situation investing, such low-volume environments can be both a challenge and an opportunity. Thinly traded floats are historically among the most responsive to newsflow, leading to rapid re-rating scenarios. As such, NMTRQ could become a case study for event-driven investors with the patience and discipline to monitor for critical catalysts.

Catalysts and Positive Outlook

Despite official liquidation, the NMTRQ ticker quietly retains several latent bullish catalysts:

• IP Monetization or Reassignment: The sale of IP for $7 million, together with the past presence of advanced clinical programs, suggests that new acquirers may seek to relist or leverage these assets, possibly returning value to existing ticker holders through successor entities.
• Sector M&A Trends: Larger biotech and pharma companies remain active hunters of distressed assets—especially late-stage or de-risked molecules. Any further interest in the 9 Meters pipeline from strategic buyers could result in litigation windfalls or asset-back rights accruing to current shareholders.
• Legal/Bankruptcy Process Outcomes: Under US bankruptcy law, there are historical examples where equity holders have received contingency payouts if liquidation recoveries exceed creditor priorities—including via litigation settlements or “stub” equities in reorganized entities.
• Biotech Sentiment Recovery: As risk appetite returns to the innovation segment of public markets, post-liquidation equities—often overlooked during the risk-off part of the cycle—can stage powerful “dead-cat” rallies on even minor positive news.

From an ESG perspective, the ongoing need for innovation in rare and orphan GI diseases is growing, with patient advocacy and regulatory fast-tracking increasingly common in the US and offshore. Any revival or acquisition of these programs could thus rapidly attract capital and collaborative dealflows.

Investment Strategies

Given the highly speculative nature of NMTRQ, distinct strategies come into play:

• Short-Term Event Monitoring: Tactical investors may position ahead of potential announcements (final IP settlement, court-ordered distributions, M&A interest), seeking sizeable leverage to any upside event from these depressed levels. The low float and extreme illiquidity can favour both.
• Medium-Term Special-Situations Holding: For those with patience, a buy-and-hold “lottery ticket” approach could suit, where optionality outweighs downside (already reflected at $0.0000/share). Historically, such situations require only one positive court or asset development to unlock meaningful value.
• Long-Term Sectoral Bet: Ultra-long horizon investors might consider exposure as a means to benefit from sector “mean reversion” scenarios or in anticipation of a restructuring/relisting, particularly if a new sponsor or acquirer seeks to unlock value for former equity.

In all cases, ideal technical positioning would be at or near the current all-time low, presenting a binary payoff profile: limited further downside, with real—but speculative—exposure to upside through binary events.

Is it the Right Time to Buy 9 Meters Biopharma?

NMTRQ stands today as one of the most intriguing asymmetry plays in the distressed biotech arena. Despite the cessation of core operations, several factors favour renewed attention: a recently validated pipeline, confirmed residual IP value through asset sales, and a persistently supportive macro environment for GI therapeutics and orphan drug innovation.

• Demonstrated Pipeline Value: $7 million in asset sale proceeds despite liquidation evidences robust interest in the innovation package.
• Event-Driven Upside: Court, M&A or technical “reboot” scenarios may present unexpected but substantial benefits for current equity holders.
• Asymmetrical Risk/Reward: With the share price at rock-bottom and a near-total washout already priced in, the balance now leans toward optionality rather than further loss.
• Sector Tailwind: Increasing demand for rare/targeted GI therapies and recent biotech market optimism create a favourable backdrop for any positive inflection.
• Technical Low: Entry at historic lows augurs well for anyone positioning for an outlier event.

In summary, while 9 Meters Biopharma remains a highly unconventional and deeply speculative equity—requiring strong risk discipline—the convergence of event-driven catalysts, undervalued IP, and a proven innovation track record suggests that this situation deserves renewed and serious scrutiny. For New Zealand investors seeking undervalued exposures to the US biotech sector’s reboot potential, NMTRQ appears to represent an excellent opportunity to consider. Should a new chapter arise for its valuable assets, this formerly overlooked ticker may yet lead a remarkable renaissance at the frontiers of medical innovation.

How to buy 9 Meters Biopharma stock in New Zealand?

Buying shares of 9 Meters Biopharma (NMTRQ) online is straightforward and secure when using a regulated broker. New Zealand investors can access international stocks like NMTRQ via two main methods: direct cash (spot) buying, where you own real shares, or trading Contracts for Difference (CFDs), which allow you to speculate on price movements without actually owning the stock. Each approach has distinct risk and cost profiles, which we’ll explain below. To help you decide, you’ll also find a broker comparison tool further down this page.

Spot buying

A cash purchase (spot buying) means you are buying and owning real 9 Meters Biopharma shares in your name through your broker. For NZ investors, typical trading fees for US-listed stocks range from a fixed NZ$5 to NZ$15 per order, depending on the platform you use. Let’s look at a concrete example:

Concrete example

Suppose the NMTRQ share price is $0.0001 USD per share (approx. NZ$0.00016), and you have NZ$1,000 to invest. Excluding local currency fluctuations and fees, you could buy approximately 6,250,000 shares (NZ$1,000 ÷ NZ$0.00016), after accounting for a NZ$5 commission.
✔️ Gain Scenario:
If the share price rises by 10% to NZ$0.000176, your shares would now be worth NZ$1,100.
Result: That’s a NZ$100 gross gain, equal to +10% on your initial investment.
Note: For NMTRQ, the share price is currently at $0.0000 and the company is in liquidation, reflecting extremely high risk.

Trading via CFD

CFD trading allows you to speculate on the price movements of 9 Meters Biopharma shares without owning them directly. With CFDs, brokers typically charge a spread (the difference between buy and sell prices) and overnight financing fees for leveraged positions. You can amplify your returns (and risks) with leverage.

CFD example

For example:
If you open a CFD position on NMTRQ with NZ$1,000 and 5x leverage, your market exposure is NZ$5,000.
✔️ Gain scenario:
If NMTRQ’s price rises by 8%, your position would gain 8% × 5 = 40%.
Result: This means a NZ$400 gain on your NZ$1,000 stake—minus possible spreads and daily financing costs.
Important: Leveraged trading also magnifies the risk of loss, and with NMTRQ’s zero liquidity and liquidation status, extreme caution is essential.

Final advice

Before buying 9 Meters Biopharma shares or trading CFDs, it’s crucial to compare the fees, trading conditions, and risk warnings of different brokers. Ultimately, your choice should reflect your investment objectives, risk tolerance, and whether you seek actual share ownership or exposure via derivatives. There’s a detailed broker comparison further down this page to help you make an informed decision.

Our 7 tips for buying 9 Meters Biopharma stock

The latest news about 9 Meters Biopharma

No trading activity or price movement for 9 Meters Biopharma shares in the last week. According to trusted OTC Markets data, the NMTRQ symbol has remained at $0.0000 without any changes in trading volume or price over the past seven days. This suggests an absence of market interest or activity, which is typical for a company under liquidation and with no ongoing operations.

All company operations remain ceased and the liquidation process is ongoing with no revival plan reported. Since filing for Chapter 7 bankruptcy in July 2023, 9 Meters Biopharma has not resumed activities, and all decisions are now under the authority of a bankruptcy trustee. As recently as this week, there are no official communications or signals regarding any restructuring, asset recovery plan, or operational resurgence that could be relevant for current or potential shareholders, including those in New Zealand.

The latest asset liquidation has been completed, returning approximately $7 million to creditors, not shareholders. Recent court filings confirmed that the company’s intellectual property and remaining assets were sold as part of the liquidation process during 2024. These proceeds are strictly allocated to creditor repayment, in accordance with US bankruptcy law, with no anticipated distribution to equity holders. This legally entrenched hierarchy places New Zealand–based investors, like all holders of ordinary shares, at the end of the claims queue.

No new product distribution, regulatory activity, or commercial announcements related to New Zealand in the last seven days. There is no evidence from official company channels or public records that any of 9 Meters Biopharma's drug development programs, such as vurolenatide or larazotide, have been revived, sold to a party with New Zealand interests, or are undergoing consideration by regulatory authorities such as New Zealand’s Medsafe.

Losses realized by NMTRQ holders may be relevant for New Zealand investors with cross-border portfolios. While the stock is now considered worthless, professional investors in New Zealand might consider reviewing potential tax implications of their loss, subject to NZ’s cross-border investment rules. However, this is a matter of personal or institutional tax structuring and does not reflect any recovery or positive market outcome regarding the underlying security.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.